Is it possible to discontinue glucocorticoids in rheumatoid arthritis with the use of synthetic disease-modifying antirheumatic drugs?
The aim of the work is to study the possibility of glucocorticoid (GC) discontinuation or their target dose achievement in patients (pts) with rheumatoid arthritis (RA) receiving conventional synthetic disease-modifying antirheumatic drugs (DMARDs). Materials and methods. 270 pts with RA (women –...
Saved in:
| Main Authors: | O. B. Iaremenko, H. M. Mykytenko |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaporizhzhia State Medical and Pharmaceutical University
2023-07-01
|
| Series: | Zaporožskij Medicinskij Žurnal |
| Subjects: | |
| Online Access: | http://zmj.zsmu.edu.ua/article/view/277503/279336 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01) -
Evaluation of the modified combined glucocorticoid toxicity index in rheumatoid arthritis: Preliminary data
by: V. V. Lebedeva, et al.
Published: (2020-02-01) -
Conventional synthetic disease-modifying antirheumatic drug use by race/ethnicity and factors associated with initiating biologics in Malaysian patients with rheumatoid arthritis
by: Suad Mohammed, et al.
Published: (2019-01-01) -
EULAR recommendation for the management of rheumatoid arthritis (2013): glucocorticoid use
by: N.V. Chichasova
Published: (2014-05-01) -
On the advisability of long-term use of low-dose glucocorticoids in elderly patients with rheumatoid arthritis
by: A. V. Gordeev, et al.
Published: (2025-06-01)